Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) traded down 4.8% during trading on Wednesday . The stock traded as low as $8.27 and last traded at $8.38, with a volume of 85,163 shares. The stock had previously closed at $8.80.

Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. TheStreet raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Finally, Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th.

The company has a 50 day moving average of $7.71 and a 200 day moving average of $6.74. The firm’s market cap is $257.55 million.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.10 million. Equities analysts anticipate that Foamix Pharmaceuticals Ltd. will post ($0.92) earnings per share for the current fiscal year.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.